Development and Manufacture of Pharmaceutical Dosage Forms for Treatment of Substance Abuse Disorders

SOL #: 75N98026R00007SBSources Sought

Overview

Buyer

Health And Human Services
National Institutes Of Health
NATIONAL INSTITUTES OF HEALTH NIDA
Bethesda, MD, 20892, United States

Place of Performance

Place of performance not available

NAICS

Research and Development in the Physical (541715)

PSC

Health R&D Services; Health Care Services; Basic Research (AN11)

Set Aside

No set aside specified

Timeline

1
Posted
Feb 17, 2026
2
Response Deadline
Mar 4, 2026, 2:00 PM

Qualification Details

Fit reasons
  • NAICS alignment with historical contract wins in similar service areas.
  • Scope strongly matches core technical capabilities and delivery model.
Risks
  • Past performance thresholds may require one additional teaming partner.
  • Potential clarification needed on staffing minimums before bid/no-bid.
Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The National Institute on Drug Abuse (NIDA), under the National Institutes of Health (NIH), is conducting a Sources Sought Notice to identify qualified small businesses capable of developing and manufacturing pharmaceutical dosage forms for the treatment of substance abuse disorders. This market research aims to inform future acquisition strategies, including potential set-asides. Responses are due March 4, 2026, at 9:00 AM Eastern Time.

Scope of Work

The selected contractor will be responsible for a comprehensive range of services related to pharmaceutical development and manufacturing, including:

  • Pre-formulation studies on drug substances.
  • Development and manufacturing of dosage forms/drug products and placebos.
  • Development and validation of analytical methods.
  • Establishing specifications for dosage forms/drug products.
  • Determining stability of finished dosage forms/drug products.
  • Maintaining storage facilities for drug substances and finished products, including controlled substances.
  • Shipping drug substances and dosage forms/drug products to designated NIDA sites.
  • Generating reports and data necessary for NIDA's Investigational New Drug (IND), New Drug Application (NDA), and/or Drug Master File (DMF) preparation.

Contract & Timeline

  • Opportunity Type: Sources Sought Notice (AN11 - Health R&D Services; Basic Research)
  • Anticipated Contract Type: Five (5) year Indefinite Delivery/Indefinite Quantity (IDIQ) Task Order (TO) type contract.
  • Set-Aside: NIDA is particularly interested in small business sources for this effort.
  • Response Due: March 4, 2026, 9:00 AM Eastern Time
  • Published: February 17, 2026

Submission & Evaluation

Interested companies must submit a capability statement demonstrating their ability to meet the project requirements. Statements should include:

  • Total number of employees.
  • Professional qualifications of key personnel.
  • Any relevant GSA Schedule or Government-Wide Acquisition Contracts (GWACs).
  • Company Name, Unique Entity ID (UEI), Physical Address, and Point of Contact information. Statements must be in Microsoft Word or Adobe PDF format, using 11- or 12-point font, 8-1/2" x 11" paper, 1" margins, and single or double spacing. The response is limited to ten (10) pages, excluding cover page, executive summary, or references. Submissions should be sent electronically to scott.duernberger@nih.gov.

Eligibility / Set-Aside

Respondents must identify their business type (e.g., small business, HUBZone, service-disabled veteran-owned, 8(a), veteran-owned, woman-owned, or small disadvantaged business) and size classification relative to the applicable NAICS code. Organizations not considered small businesses under the relevant NAICS code should not respond. If domestic sources are available and capable, evaluation preferences may be applied in accordance with FAR 25.

Additional Notes

This is a market research notice, not a solicitation for proposals. The Government is not obligated to acknowledge receipt of responses or provide feedback. Responses will not be considered adequate for a future solicitation. Do not include proprietary, classified, confidential, or sensitive information.

People

Points of Contact

Scott DuernbergerPRIMARY
Joshua T LazarusSECONDARY

Files

Files

Download

Versions

Version 1Viewing
Sources Sought
Posted: Feb 17, 2026
Development and Manufacture of Pharmaceutical Dosage Forms for Treatment of Substance Abuse Disorders | GovScope